Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Tyra Biosciences Q3 2026 Results: Net Loss of $51.1M, Loss Widens

Tyra Biosciences reported a net loss of $51.1 million for the third quarter of 2026, driven by increased research and development expenses. The company significantly strengthened its balance sheet during the first nine months of 2026, raising over $524 million through an at-the-market offering and a separate issuance of common stock and pre-funded warrants.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-51.1-29.9
EPS (diluted, $ a share)$-0.74$-0.50

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: TYRA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Tyra Biosciences, Inc.: key numbers

Share price
$19.74Close, Nov 16
Market cap
$1.36B
Shares outstanding
69.08MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Tyra Biosciences, Inc.

All →
8:03 AM ET 8-K
Financial Results

Tyra Biosciences Financial Results

Tyra Biosciences reported third quarter 2026 financial results, highlighting a cash position of $700.5 million following a $400 million financing. The company is advancing its '3x3 strategy' for dabogratinib, including positive initial Phase 2 results in NMIBC and preparations for Phase 3 development.

“2026 has been a defining year for TYRA. With the initial results from SURF302 in the ablative setting, we believe dabogratinib has the potential to be the first oral FGFR3-selective inhibitor in intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), reinforcing our conviction in the potential of precision FGFR3 inhibition to fundamentally change the treatment paradigm for patients.”

Todd Harris, PhD, President and Chief Executive Officer

“With a strengthened balance sheet following our $400 million financing, TYRA is entering its next phase of growth from a position of strength. We now have the financial resources to advance our dabogratinib 3x3 strategy through late-stage clinical development.”

Todd Harris, PhD, President and Chief Executive Officer
6:04 AM ET 8-K
Capital Raise

Tyra Biosciences Capital Raise of $400M

Tyra Biosciences entered into an underwriting agreement to raise approximately $400 million through the sale of 9,079,000 shares of common stock and 9,078,529 pre-funded warrants. The offering was led by RA Capital Management and includes participation from several institutional investors to fund the development of dabogratinib and other pipeline programs. The common stock is priced at $22.03 per share, with the offering expected to close on September 15, 2026.

Value
$400M
Counterparty
Jefferies LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.